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Background: Combination therapy consisting of basal insulin and oral hypoglycemic agents (OHAs) is effective for
the treatment of type 2 diabetes (T2DM) that cannot be adequately controlled using OHAs alone. Though basal
insulin with metformin or sulfonylurea is an effective therapy, it cannot reduce postprandial glycemia without the
risk of hypoglycemia. We examined a two-step regimen consisting of the addition of postprandial hypoglycemic
agents (an alpha-glucosidase inhibitor and a glinide) in patients whose T2DM was poorly controlled using basal
insulin therapy.
Methods: Inpatients between the ages of 30–79 years who had T2DM and an HbA1c level of more than 7.0% were
recruited. The patients were treated with once-daily insulin glargine with or without metformin, depending on
the patient’s age and renal function. Insulin glargine was titrated to achieve a target fasting glucose level of
70–130 mg/dL as a first step (STEP0). If the 2-hour postprandial glucose (PBG) level was higher than the target of
180 mg/dL, miglitol treatment (150 mg/day) was initiated, with dose adjustments (75–225 mg) allowed depending
on abdominal symptoms and the PBG (STEP1). If the PBG of the patients remained higher than the target after
3 days of treatment, mitiglinide (30 mg/day, titrated up to 60 mg) was added (STEP2). We then evaluated the
proportion of patients who achieved the target PBG before and after the two-step regimen. Continuous Glucose
Monitoring (CGM) was performed throughout the two-step protocol in most of the patients.
Results: Of the 16 patients who were recruited (median age, 67.0 [58.0-71.0] years; body mass index, 25.0 [22.0-27.9]
kg/m2; HbA1c level at admission, 9.1% [8.35-10.4%]), 1 patient (6.25%) achieved the target PBG at STEP 0 and 14
patients (87.5%) had achieved the target PBG at the end of the treatment protocol (P = 0.002). CGM showed a
significant decrease in the glucose level at each step of the protocol. The standard deviations in the CGM glucose
levels for 24 hours, MAGE, and M-value also improved.
Conclusions: The two-step addition of postprandial hypoglycemic agents to basal insulin therapy is potentially
effective and safe for decreasing both the fasting and postprandial glucose levels.
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Type 2 diabetes is characterized by both decreased insulin
secretion and sensitivity [1]. The impairment of insulin se-
cretion derived from β cell dysfunction is a progressive
process that occurs before diagnosis and throughout the
course of type 2 diabetes [2,3]. Therefore, many patients
who are initially treated with oral hypoglycemic agents
(OHAs) eventually require a treatment strategy that in-
cludes insulin to counteract persistent hyperglycemia.
One treatment strategy that includes insulin is the com-
bination of basal insulin with oral hypoglycemic agents.
Historically, a regimen combining basal insulin with sulfo-
nylurea and metformin has been frequently used. Using
this regimen, the insulin dose can be easily titrated to
minimize the number of hypoglycemic episodes and
weight gain, compared with multiple insulin injections
or mixed insulin therapy [4,5]. However, a drawback of
this regimen is that it provides poor support against sus-
tained post-breakfast hyperglycemia (a situation that is
often observed in patients with poor glycemic control
[6,7]) and postprandial hyperglycemia, resulting in glucose
fluctuations that can increase the risks of both cardiovas-
cular disease [8-11] and microvascular disease [12,13].
Attempts to lower the postprandial glucose level by in-
creasing the dose of basal insulin can lead to an increased
risk of severe hypoglycemia during the night and early
morning, which might also be associated with an in-
creased risk of cardiovascular disease [14,15].
Accordingly, we have proposed a regimen consisting of
a two-step administration of postprandial hypoglycemic
agents, namely an alpha-glucosidase inhibitor and a gli-
nide, to basal insulin therapy to target postprandial hyper-
glycemia. We then conducted a pilot study to examine the
safety and efficacy of this regimen.
Methods
Patients
We enrolled patients with type 2 diabetes who were hos-
pitalized at the National Center for Global Health and
Medicine Center Hospital between November 2011 and
August 2013. Candidate subjects were between the ages
of 30–79 years and had insufficient glucose control
(HbA1c ≧ 7.0%). Patients with severe renal dysfunction
(estimated glomerular filtration rate <30 mL/min/1.73 m2
or continuous hemodialysis), severe liver dysfunction, type
1 diabetes, glutamic acid decarboxylase antibody positiv-
ity, malignancy, or other causes of hyperglycemia were ex-
cluded from the present study.
All the patients provided written informed consent a few
days after hospitalization and prior to enrollment in the
trial. The study protocol was approved by the ethics com-
mittee of the National Center of Global Health and Medi-
cine Center Hospital and was implemented in accordance
with the provisions of the Declaration of Helsinki.Study design
STEP 0
First, patients were treated with diet therapy (25–30 kcal/
ideal body weight/day: carbohydrates, 60%-67.5%; fat, 21%-
24.2%; protein, 11.2%-18.4%) and insulin glargine with
metformin. The metformin dosage was set as high as pos-
sible after considering the patient’s age, renal function, and
other adverse effects. Metformin was not administered to
subjects who were older than 75 years of age or who had a
serum creatinine level higher than 1.3 mg/dL (for men) or
1.2 mg/dL (for women).
For the basal insulin therapy, insulin glargine was
used. The dose was titrated at the physician’s discretion
to achieve a target fasting blood glucose (FBG) level be-
tween 70–130 mg/dL. An evaluation of the daily glucose
profiles indicated that at least 5 days after admission
were required to regulate the FBG at the target level. If
the postprandial 2-hour blood glucose (PBG) level corre-
sponded to the target value (lower than 180 mg/dL), the
study protocol ended (STEP 0 responder). Patients who
did not achieve the target PBG value were additionally
treated with postprandial hypoglycemic agents (refer to
STEP 1 and STEP 2 below). The target PBG was defined
according to the American Diabetes Association’s rec-
ommendation [16].
STEP 1
On day 1, miglitol (150 mg/day, 50 mg administered im-
mediately before every meal) was administered and the
PBG was evaluated. If the target PBG was not achieved
on day 1, the dose of miglitol was increased to 225 mg/
day (75 mg administered immediately before every meal)
on day 2. If the patient experienced gastrointestinal symp-
toms, the dose of miglitol was decreased to a tolerable
dose on day 3. The PBG was evaluated on day 2 or day 3.
If the PBG was under 180 mg/dL, the study protocol was
regarded as having been successful at STEP 1.
STEP 2
For patients who failed to achieve the target PBG with
miglitol, mitiglinide (30 mg/day, 10 mg administered im-
mediately before every meal) was added to the treatment
regimen on day 4 (or day 5). If the target PBG was not
reached, the dosage of mitiglinide was increased to 60 mg/
day (20 mg administered immediately before every meal)
on day 5 (or day 6) and the PBG was evaluated.
Biochemical and clinical measurements
We calculated the BMI using the body height and weight
of each patient. The 24-h urine C peptide and serum C
peptide levels were measured before and 6 minutes after
the intravenous injection of 1 mg of glucagon (glucagon
stimulation test).
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checked before and 2 hours after each meal and before
sleep (7-point SMBG) using a Nipro StatStrip XP (Nova
Biomedical K.K.). The M-value was calculated using the
following equation:












(MGR =M-value for glucose reading, MW= correction
factor, BSti = glucose reading at time ti, Gmax =maximum
glucose reading, Gmin =minimum glucose reading) [17,18].
The patients were observed using continuous glucose
monitoring (CGMS® System Gold™; Medtronic Inc.); the
CGMS device was calibrated four times a day. The results
were then used to calculate the 24-h average, the standard
deviation (SD) of the 24-h values, the 24-h area under the
curve (AUC), every 4-h postprandial value, and from mid-
night to early morning (from 0:00 AM to 8:00 AM), andFigure 1 Enrollment and outcomes.the mean amplitude of glycemic excursion (MAGE [19])
using the glucose values observed every 5 minutes. We
failed to obtain CGM records in 2 of the 16 patients be-
cause of technical difficulties.
Primary and secondary outcomes
The primary endpoint was the change in the proportion of
patients who reached the target PBG before and after the
addition of the postprandial hypoglycemic agents (STEP 0
vs. end of protocol). We also calculated the M-value,
MAGE, and the averages and SDs of the CGM data ob-
tained on the days on which each of the steps were evalu-
ated. We also compared the patient backgrounds of those
in whom the treatment was or was not a success.
Statistical analysis
Exact McNemar test was used to compare the propor-
tion of patients who achieved the target PBG at STEP 0
and at the end of the protocol. Continuous variables
were compared using the Wilcoxon rank sum test. A
two-sided P value <0.05 was regarded as significant. The
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tile ranges. The statistical analysis was performed using
Stata IC 11.
Results
We enrolled 18 patients with type 2 diabetes who had been
hospitalized in our institution. Two patients were excluded:
one patient was diagnosed as having preclinical Cushing
syndrome, and the other was excluded because of the pres-
ence of an insulin autoimmune antibody. One patient
reached the target PBG at STEP 0 and did not proceed to
the next step in the protocol (Figure 1) (Table 1). Of the 15
patients who were treated with miglitol, 8 patients reached
the target PBG at the STEP 1 evaluation. Mitiglinide was
then added to the treatments of the 7 patients who failed
to reach the target PBG using the STEP 1 treatment; 5 of
these patients achieved the target PBG at the STEP 2
evaluation. Finally, 1 of the 16 patients achieved the tar-
get PBG at STEP 0 and 14 patients achieved the target
PBG at the end of the study protocol (6.25% vs. 87.5%,
P = 0.0002). The 7-point SMBG and CGM were also im-
proved (Figure 2). The characteristics of the patients
who reached the target PBG at STEP 1 and the patients
who proceeded to STEP 2 are presented in Additional
file 1: Table S1.
At STEP 0, the 7-point glucose monitoring values ex-
hibited sustained levels of post-breakfast hyperglycemia.
With the administration of miglitol, the 7-point glucose
monitoring values from after breakfast until after dinner
were suppressed, but the values before sleep and before
breakfast did not decrease significantly (Figure 3A). WhenTable 1 Characteristic of patients (N = 16)
Demographics
Age (years)a 67.0 (58.0-71.0)
Sex (men/women) 11/5
BMI (kg/m2)a 25.0 (22.0-27.9)
Duration of diabetes (years)a 14.0 (8.5-24.75)
HbA1c (%)a 9.1 (8.3-10.4)
Glycated albumin (%)a 22.9 (19.8-26.8)
eGFR (mL/min/1.73 m2)a 70.0 (62.6-82.4)








Administration of metformin at STEP 0b 10
a: Median (interquartile range), b: Numbers.the glycemic profiles were examined more precisely using
CGM, the 24-h AUC and each of the 4-h postprandial
AUC values were significantly decreased. The AUC from
0:00 AM to 8:00 AM (from evening until before breakfast)
remained unchanged at the STEP1 evaluation after the
addition of miglitol, compared with the values at STEP0
(Figure 3B).
Similarly, compared with STEP 1, the 7-point glucose
monitoring values from after lunch through until after
dinner were significantly decreased at the STEP 2 evalu-
ation (Figure 3C), the same day of CGM profile was de-
scribed (Figure 3D). The 24-h AUC, the 4-h after-lunch
AUC, and the 4-h after dinner AUC recorded using CGM
were significantly decreased at the STEP 2 evaluation. The
details of the CGM data for each step are described in an
Additional file 2: Table S2.
The markers of glucose fluctuations, namely the SDs
of the glucose levels for 24-h and MAGE, improved and
the M-values were also decreased at the end of protocol
(Table 2).
Two patients were unable to achieve the target PBG.
One patient was a 78-year-old man; although he exhib-
ited a comparably sufficient endogenous insulin level, he
was obese and could not use metformin because of his
age. The other patient was a 61-year-old woman; she
had a long duration of diabetes, and her endogenous in-
sulin level was almost depleted. Both of these patients
had highly fluctuating glucose levels, as shown by the
M-value and the SDs of the 24-h data and MAGE ob-
tained using CGM (Table 3).
No severe hypoglycemic events occurred. Regarding
the CGM data, hypoglycemia of less than 70 mg/dL was
rarely recorded from midnight until daytime (Table 2).
Discussion
Postprandial hyperglycemia can have a harmful effect on
the cardiovascular outcome. In this study, ten patients
were treated with as high a dose of metformin as they
could tolerate; metformin is recommended as a drug of
first choice [16] in combination with insulin glargine at
STEP 0. The remaining six patients were treated with in-
sulin glargine alone at STEP 0 because of an advanced
age or a reduced renal function. The administration of
basal insulin with or without metformin decreases the
fasting glucose level and the overall glycemic profile, but
in our cases, it was insufficient to postprandial hypergly-
cemia in 15 of the 16 cases. Many studies have discussed
the combination of basal insulin with metformin or sufo-
nylurea or both drugs [5,20-22]. However, their mecha-
nisms of action can make them insufficient to prevent
postprandial hyperglycemia. Consequently, we prescribed
miglitol and mitiglinide as a two-step treatment. Using
our treatment regimen, 14 of the 16 patients achieved the
target PBG as defined by the American Diabetes
A B
All  the patients at STEP0 (N=14)
All the patients at the end of the treatment
regimen(N=14) 
All the patients at STEP0 (N=16)
All the patients at the end of the treatment 
regimen (N=16) 




































10 18 614 22 24
Figure 2 Median 7-point SMBG and CGM of all the patients at STEP0 and at the end of the treatment regimen. A. Median 7-point SMBG
of all the patients at STEP 0 and at the end of the treatment regimen. Black line: all the patients at STEP 0, Gray line: all the patients at the end of
the treatment regimen. BB: before breakfast, AB: after breakfast, BL: before lunch, AL: after lunch, BD: before dinner, AD: after dinner, BS: before
sleep. *value of SMBG of all the patients at STEP 0 vs. those at the end of the treatment regimen P < 0.05. B. Median CGM of all the patients at STEP
0 and at the end of the treatment regimen. Black line: all the patients at STEP 0, Gray line: all the patients at the end of the treatment regimen.
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STEP1 before administration of Miglitol (N=15)
STEP1 after administration of Miglitol (N=15)







STEP2 before administration of  Mitiglinide (N=7)
STEP2 after administration of Mitiglinide(N=7)
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STEP1 before administration of Miglitol (N=13)
STEP1 after administration of Miglitol (N=13)
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STEP2 before administration of Mitiglinide (N=5)
STEP2 after administration of Mitiglinide (N=5)
Figure 3 Median 7-point SMBG and CGM at STEP 1 and STEP 2. A. Median 7-point SMBG of patients who proceeded to STEP 1 (before and
after administration of Miglitol). Blue line: The patients who proceeded to STEP 1 before administration of Miglitol, Red line: The patients who
proceeded to STEP 1 after administration of Miglitol. BB: before breakfast, AB: after breakfast, BL: before lunch, AL: after lunch, BD: before dinner,
before AD: after dinner, BS: before sleep. *value of SMBG of patients who proceeded to STEP 1 before vs. after administration of Miglitol P < 0.05.
B. Median CGM of patients who proceeded to STEP1 (before and after administration of Miglitol). Blue line: The patients who proceeded to STEP1
before administration of Miglitol, Red line: The patients who proceeded to STEP1 after administration of Miglitol. C. Median 7-point SMBG of
patients who proceeded to STEP 2 (before and after administration of Mitiglinide). Red line: The patients who proceeded to STEP 2 before
administration of Mitiglinide, Green line: The patients who proceeded to STEP 2 after administration of Mitiglinide. BB: before breakfast, AB: after
breakfast, BL: before lunch, AL: after lunch, BD: before dinner, AD: after dinner, BS: before sleep. *value of SMBG of patients who proceeded to STEP
2 before vs. after administration of Mitiglinide P < 0.05. D. Median CGM of patients who proceeded to STEP 2 (before and after administration of
Mitiglinide). Red line: The patients who proceeded to STEP 2 before administration of Mitiglinide. Green line: The patients who proceeded to STEP
2 after administration of Mitiglinide.
Ihana et al. Diabetology & Metabolic Syndrome 2014, 6:48 Page 5 of 8
http://www.dmsjournal.com/content/6/1/48
Table 2 Results of area under the curve of CGM and




At the end of
this protocol
Results of continuous glucose
monitoring
Number of patients 14 14
















AUC for 8-h from midnight to




24-h mean glucose levels (mg/dL) 169.7 124.7*
(142.6-181.1) (118.8-146.4)








Proportion of time (%) in
hypoglycemia (<70 mg/dL)
0 0
MAGE 91.1 (79.1-119.6) 61.3* (50.2-72.4)
Results of 7-point SMBG
Number of patients 16 16
M-value 28.8 (21.4-52.5) 8.7 *(5.0-15.7)
Median (interquartile range)
*P < 0.05
CGM data were analyzed in a total of 14 patients because of missing CGM
data in 2 of the 16 patients.
Table 3 Characteristics of patients who did or did not









Age (years) 67.0 (55.5-70.5) 78 61
Sex (men/women) 10/4 man woman
BMI (kg/m2) 25.0 (21.8-27.8) 28.0 22.1
Duration of diabetes (years) 13.0 (7.0-21.5) 12 40
HbA1c (%) 9.2 (8.7-11.2) 8.3 8.2
Glycated albumin (%) 23.0 (20.2-29.4) 21.1 19.8
eGFR (mL/min/1.73 m2) 70.5 (58–84.2) 70.0 67.2
Urinary C-peptide excretion
(μg/day)
43.5 (24.8-69.6) 67.4 14.4
C-peptide
(Glucagon stimulated test)
at 0 minutes (ng/mL) 0.9 (0.75-1.45) 1.9 0.4
at 6 minutes (ng/mL) 2.3 (1.45-2.9) 3.0 0.8
Δ (ng/mL) 1.1 (0.65-1.40) 1.1 0.4
Insulin glargine (units/day) 14 (8.5-18.5) 12 13
Insulin glargine (units/kg) 0.2 (0.17-0.26) 0.15 0.23
MAGE at the final CGM
evaluation
60.5 (46.9-69.2) 61.3 87.6
(N = 12)
M-value at the final SMBG
evaluation
8.4 (4.3-14.1) 24.2 18.0
Median (interquartile range).
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of the hospital stay might have contributed to the gradual
improvement in the glucose level and might have influ-
enced the achievement of the target PBG, the fact that
most of the subjects eventually attained an ideal glycemic
control using this regimen is noteworthy. In addition,
CGM highlighted the precise profiles of glucose excursion,
showing the effectiveness of the miglitol and mitiglinide in
lowering daytime blood glucose levels without causing
hypoglycemia during the night as well as showing the im-
provement in glucose fluctuations as a result of treatment
with the two drugs in more detail.
The two patients who were unable to attain the target
PBG suggest that the present regimen has some limita-
tions. One patient was an obese, elderly man who was
unable to take metformin because of his age. In thispatient, insulin resistance might have limited the effect
of mitiglinide. The other patient was a woman with the
lowest serum C-peptide at 6 minutes in the glucagon test.
For this patient, the effect of mitiglinide might have been
limited by the impaired secretion of insulin.
In this study, we used two postprandial hypoglycemic
agents. Alpha-glucosidase inhibitors, which delay the ab-
sorption of carbohydrates in food, decrease the postprandial
glucose level without inducing the secretion of insulin [23].
As a result of this unique mechanism, alpha-glucosidase is
effective for patients even if they have a comparatively long
duration of diabetes and a severe deterioration of insulin
secretion. In addition, miglitol provides incretin effects in-
duced by GLP-1 secretion from L-cells [24]. Glinide is a
short-acting insulin secretagogue that functions through
the KATP channel inhibition of β cells [25]. Mitiglinide also
suppresses postprandial free fat acid levels [26]. These
drugs decrease postprandial hyperglycemia effectively while
causing fewer episodes of hypoglycemia and are relatively
safe for patients with renal dysfunction and for elderly
patients, in addition to being safe for long-term use.
Numerous studies have supported the effectiveness of
basal insulin with sulfonylurea or metformin [5,20-22]
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use of insulin glargine with postprandial hypoglycemic
agents. Kim et al. reported the efficacy of adding either
nateglinide or acarbose to insulin glargine, resulting in
a 7-point reduction in the SMBG and with no differ-
ence in glucose variability between nateglinide and
acarbose [27]. Hirose et al. investigated the effect of
mitiglinide with insulin glargine after switching from
multiple daily injections and reported that 15 out of 30
patients maintained a fair glucose control after switch-
ing to mitiglinide [28,29]. These reports suggested the
effectiveness of using postprandial hypoglycemic
agents with long-acting basal insulin and also indicated
the limitations of the addition of single postprandial
hypoglycemic agents.
To improve postprandial hypoglycemia, dipeptidyl
peptidase-4 (DPP-4) inhibitors and GLP-1 analogs are
other choices for use in combination with basal insulin
[30,31]. We are also attempting to construct new regimens
composed of basal insulin and multiple hypoglycemic
agents, including DPP-4 inhibitors or GLP-1 analogs [32].
Initiating basal insulin therapy in patients with poor
glycemic control after the use of metformin is supported
by the American Diabetes Association [33,34] and the
European Association for the Study of Diabetes [34]. In
addition, this treatment regimen may lead to better
glycemic control, compared with only basal insulin with
metformin, because both the fasting and postprandial
blood glucose levels can be controlled. This regimen
might also serve as a go-between for frequent insulin
injections therapy.
This study had several limitations including the rela-
tively small number of subjects, the absence of a control
group, and the short-term results for inpatients. The pa-
tients’ satisfaction level after receiving this regimen and
long-term diabetic complications, cardiovascular disease,
and mortality also need to be evaluated. In addition,
larger studies are needed to evaluate the reduction of
hypoglycemia associated with this regimen. Confirming
this hypothesis, further studies are required to confirm
the efficacy of this regimen in outpatients; furthermore,
the regimen should be simplified before being adminis-
tered to outpatients.
Once such points have been clarified, our structured
treatment regimen might be beneficial for many type 2
diabetes patients requiring insulin therapy.
Conclusions
In conclusion, in a pilot study of a two-step regimen
consisting of the addition of postprandial hypoglycemic
agents, more than 80% of the patients achieved a good
glucose profile, indicating the potent efficacy of the two-
step administration of postprandial hypoglycemic agents
with basal insulin therapy.Additional files
Additional file 1: Table S1. Characteristics of the patients who reached
the target PBG at STEP 1 and the patients who proceeded to STEP2.
Additional file 2: Table S2. Detailed results of area under the curve for
Continuous Glucose Monitoring and glucose fluctuation STEP 1 and STEP 2.
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